Journal article
Clinicopathologic risk factor distributions for MLH1 promoter region methylation in CIMP-positive tumors
AJ Levine, AI Phipps, JA Baron, DD Buchanan, DJ Ahnen, SA Cohen, NM Lindor, PA Newcomb, C Rosty, RW Haile, PW Laird, DJ Weisenberger
Cancer Epidemiology Biomarkers and Prevention | Published : 2016
Abstract
Background: The CpG island methylator phenotype (CIMP) is a major molecular pathway in colorectal cancer. Approximately 25% to 60% of CIMP tumors are microsatellite unstable (MSI-H) due to DNA hypermethylation of the MLH1 gene promoter. Our aim was to determine if the distributions of clinicopathologic factors in CIMP-positive tumors with MLH1 DNA methylation differed from those in CIMP-positive tumors without DNA methylation of MLH1. Methods: We assessed the associations between age, sex, tumor-site, MSI status BRAF and KRAS mutations, and family colorectal cancer history with MLH1 methylation status in a large population-based sample of CIMP-positive colorectal cancers defined by a 5-marke..
View full abstractGrants
Awarded by National Institutes of Health
Funding Acknowledgements
This work was supported by NIH/NCI grant R01 CA118699 (to P.W. Laird). This work was also supported by grant UM1 CA167551 (to R.W. Haile, M.A. Jenkins, N.M. Lindor) from the NCI and through the cooperative agreements with the following CCFR centers: Australasian Colorectal Cancer Family Registry (U01 CA074778, to J.R. Jass; U01/U24 CA097735, to J.L. Hopper), USC Consortium Colorectal Cancer Family Registry (U01/U24 CA074799; to R.W. Haile), Mayo Clinic Cooperative Family Registry for Colon Cancer Studies (U01/U24 CA074800; to N.M. Lindor), Ontario Registry for Studies of Familial Colorectal Cancer (U01/U24 CA074783; to S. Gallinger), and Seattle Colorectal Cancer Family Registry (U01/U24 CA074794; to J.D. Potter and P.A. Newcomb). The Jeremy Jass Memorial Pathology Bank provided CCFR paraffin-embedded tissue and pathology-related variables for this study.